Most WT1 peptide-based vaccines previously tested in patients with cancer contained only human leukocyte antigen (HLA)-I epitopes and, therefore, only elicited WT1-specific cytotoxic (CD8+) T lymphocytes [15–21]. This evidence concerns the gene CD8A and cancer.